Moderna Shares Jump on Melanoma Vaccine Trial Readout
Moderna shares surged after a melanoma vaccine trial delivered what observers called a landmark moment, moving markets and signaling clinically meaningful momentum for the mRNA oncology platform.
Topic
Oncology Drug Development
Topic